CAMBRIDGE, Mass., Sept. 16, 2025 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel, targeted therapies for cancers with unmet ...
KTX-1001 is a selective inhibitor of NSD2, also known as MMSET, a histone methyltransferase frequently dysregulated in patients with the t(4;14) chromosomal translocation, a high-risk subtype of ...
Funds raised will be used to demonstrate clinical validation and proof-of-concept in t(4;14) multiple myeloma with KTX-1001 monotherapy and KTX-1001 combination regimens with existing standard-of-care ...
K36 Therapeutics has come out of the gates with $30 million in venture funding to back a small-molecule oral treatment from Novartis. The Cambridge, Massachusetts, biotech emerged Thursday to take its ...
CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple ...
CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel, targeted therapies for cancers with unmet medical ...
The MarketWatch News Department was not involved in the creation of this content. KTX-2001 being evaluated both as a monotherapy and in combination with darolutamide in metastatic castration-resistant ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
CAMBRIDGE, Mass., Dec. 3, 2024 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET / NSD2 inhibitor KTX-1001 for t(4;14) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results